CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 117 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,205,365 | +1377.5% | 566,700 | +392.7% | 1.48% | +1802.6% |
| Q3 2021 | $420,000 | -41.4% | 115,015 | -17.8% | 0.08% | -69.9% |
| Q3 2019 | $717,000 | -90.2% | 140,000 | -74.5% | 0.26% | -87.2% |
| Q1 2019 | $7,304,000 | +28.0% | 550,000 | -24.1% | 2.02% | -5.0% |
| Q4 2018 | $5,705,000 | -26.2% | 725,000 | +3.9% | 2.13% | +8.2% |
| Q3 2018 | $7,735,000 | -17.4% | 698,100 | +0.1% | 1.97% | -18.8% |
| Q2 2018 | $9,360,000 | +8.4% | 697,500 | +4.9% | 2.42% | -1.9% |
| Q1 2018 | $8,638,000 | +41.2% | 665,000 | 0.0% | 2.47% | +26.1% |
| Q4 2017 | $6,118,000 | +14.2% | 665,000 | 0.0% | 1.96% | +3.4% |
| Q3 2017 | $5,356,000 | – | 665,000 | – | 1.89% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |